Martin Madaus Net Worth

The estimated Net Worth of Martin D Madaus is at least $2.64 Milhão dollars as of 14 June 2024. Martin Madaus owns over 1,615 units of Quanterix Corp stock worth over $55,679 and over the last 15 years he sold QTRX stock worth over $2,424,994. In addition, he makes $161,725 as Lead Independent Director at Quanterix Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Martin Madaus QTRX stock SEC Form 4 insiders trading

Martin has made over 33 trades of the Quanterix Corp stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 1,615 units of QTRX stock worth $201,778 on 14 June 2024.

The largest trade he's ever made was buying 89,667 units of Quanterix Corp stock on 10 August 2022 worth over $755,893. On average, Martin trades about 4,292 units every 95 days since 2009. As of 14 June 2024 he still owns at least 4,613 units of Quanterix Corp stock.

You can see the complete history of Martin Madaus stock trades at the bottom of the page.

Martin Madaus biography

Dr. Martin D. Madaus Ph.D. serves as Lead Independent Director of the Company. Dr. Madaus previously served as our Executive Chairman from November 2010 to June 2014, as our Chief Executive Officer from October 2011 to July 2012 and as our President from June 2011 to July 2012. Since February 2019, he has served as Operating Executive to The Carlyle Group, a multinational private equity, alternative asset management and financial services corporation. From June 2014 to February 2019, Dr. Madaus served as Chairman and Chief Executive Officer at Ortho-Clinical Diagnostics, Inc., a diagnostics company that makes products and diagnostic equipment for blood testing. Previously, Dr. Madaus was the Chairman, President and Chief Executive Officer of Millipore Corporation (MIL), a life sciences company serving the bioscience research and biopharmaceutical manufacturing industry, from January 2005 to July 2010, when Millipore was acquired by Merck KGaA. From July 2009 to May 2015, Dr. Madaus served as a member of the board of directors of Mettler Toledo International, a manufacturer of scales and analytical instruments. Dr. Madaus currently serves as a member of the board of directors of Syneron Candela, a private medical technology company. Dr. Madaus received a Doctor of Veterinary Medicine from the University of Munich in Germany and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover in Germany. Dr. Madaus's qualifications for service as a member of our board of directors include his extensive public and private company board experience and his substantial knowledge of and managerial experience in the diagnostics industry.

What is the salary of Martin Madaus?

As the Lead Independent Director of Quanterix Corp, the total compensation of Martin Madaus at Quanterix Corp is $161,725. There are 8 executives at Quanterix Corp getting paid more, with E. Kevin Hrusovsky having the highest compensation of $3,631,000.

How old is Martin Madaus?

Martin Madaus is 60, he's been the Lead Independent Director of Quanterix Corp since 2014. There are 7 older and 12 younger executives at Quanterix Corp. The oldest executive at Quanterix Corp is Dr. David R. Walt Ph.D., 68, who is the Co-Founder, Chairman of Scientific Advisory Board & Independent Director.

What's Martin Madaus's mailing address?

Martin's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.

Insiders trading at Quanterix Corp

Over the last 7 years, insiders at Quanterix Corp have traded over $25,118,881 worth of Quanterix Corp stock and bought 1,481,095 units worth $18,701,541 . The most active insiders traders include David R Walt, Paul M Meister, eKeith Crandell. On average, Quanterix Corp executives and independent directors trade stock every 7 days with the average trade being worth of $100,483. The most recent stock trade was executed by Masoud Toloue on 13 August 2024, trading 19,000 units of QTRX stock currently worth $207,100.

What does Quanterix Corp do?

quanterix offers an ultra-sensitive diagnostic platform capable of measuring individual proteins at concentrations 1000 times lower than the best immunoassays available today. the single molecule array (simoa™) technology at the heart of the platform enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening up new applications to address significant unmet needs in life science research, in-vitro diagnostics, companion diagnostics, blood screening, and more. quanterix is a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at tufts university by dr. david walt, scientific founder of quanterix and illumina (nasdaq: ilmn).

Complete history of Martin Madaus stock trades at Repligen, Mettler-Toledo International, eQuanterix Corp

Quanterix Corp executives and stock owners

Quanterix Corp executives and other stock owners filed with the SEC include:

• E. Kevin Hrusovsky,
  Chairman of the Board, President, Chief Executive Officer
• John Fry,
  General Counsel, Secretary
• Amol Chaubal,
  Chief Financial Officer
• E. Kevin Hrusovsky,
  Chairman & CEO
• Dawn Mattoon,
  Senior Vice President - Research Products
• David Duffy,
  Senior Vice President, Research & Development and Chief Technology Officer
• Sarah Hlavinka,
  Independent Director
• Mark Roskey,
  Senior Vice President - Commercial and Accelerator
• Martin Madaus,
  Lead Independent Director
• Paul Meister,
  Independent Director
• Keith Crandell,
  Independent Director
• Marijn Dekkers,
  Independent Director
• David Walt,
  Independent Director
• Dr. David R. Walt Ph.D.,
  Co-Founder, Chairman of Scientific Advisory Board & Independent Director
• William Geist,
  Chief Operating Officer
• Dr. Masoud Toloue Ph.D.,
  Pres, CEO & Director
• Dr. Dawn R. Mattoon Ph.D.,
  Sr. VP of Diagnostics
• Dr. Mark T. Roskey Ph.D.,
  Sr. VP of Strategic Partnerships
• Dr. David C. Duffy Ph.D.,
  Sr. VP of R&D and CTO
• Michael A. Doyle,
  CFO & Treasurer
• Masoud Toloue,
  Pres & Head of Diagnostics Bus.
• David Panzerella,
  VP of Sales
• William Geist,
  Chief Operating Officer
• Bruce J. Bal,
  VP of Operations, Service & Quality
• John J. Fry,
  Gen. Counsel & Corp. Sec.
• Brian J Blaser,
  
• Shawn Stetson,
  Interim CFO and Treasurer
• Venture Fund Vi Lparch Vent...,
  
• Ventures Fund 2004 L P Flag...,
  
• Capital Venture Investors, ...,
  
• Ernest Orticerio,
  SVP Finance and Corporate Dev
• Douglas G. Cole,
  
• John M Connolly,
  
• Jackson Streeter,
  SVP, Corp Dev & Strategy
• Bruce J Bal,
  VP of Ops, Service and Quality
• Joseph Driscoll,
  Chief Financial Officer
• Amee Desjourdy,
  Chief Human Resource Officer
• Laurie J Olson,
  
• Michael A Doyle,
  CFO and Treasurer
• Masoud Toloue,
  President & CEO
• Karen Flynn,
  
• William P Donnelly,
  
• Vandana Sriram,
  Chief Financial Officer
• Jeffrey Thomas Elliott,